HENDERSON, Nev. , July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program, tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The... Read More

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q ® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the... Read More

HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited ( NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two... Read More

Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of " Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats " in BMC Veterinary Research. This is the first study to report the detection of nucleosomes... Read More

Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31 , 2025. Volition management will host a conference call tomorrow, May 16... Read More

Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev. , May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found... Read More

HENDERSON, Nev. , May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre , has issued a commercial update on Volition's Nu.Q® NETs product. A Message from our Chief Commercial Officer As was stated in our shareholder update recently, 2025 is a pivotal year for Volition as we focus on commercializing... Read More

HENDERSON, Nev. , April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds , has issued a Shareholder Letter providing a business update. A Message from our Chief Executive Officer 2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q®... Read More

Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31 , 2024. Volition management will host a... Read More

Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),... Read More

HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025 , at 10:00 AM ET , featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter , Chief Medical Officer and Dr. Jake Micallef , Chief Scientific Officer. To register, click here. This... Read More

Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the purchase and sale of (i) 2,363,636... Read More

Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev. , March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update.... Read More

Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could... Read More

"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market 1 HENDERSON, Nev. , March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, " Lung Cancer: Hope of a Brighter Tomorrow ."... Read More

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium , from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44 th Annual ISICEM ("International Symposium on Intensive Care & Emergency Medicine") Congress in... Read More

HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan , to include Volition's chemiluminescent immunoassay (ChLIA) version of the Test via the Immunodiagnostic Systems (IDS) i10®... Read More

Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev. , March 11, 2025 / PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrollment in a clinical study evaluating the company's proprietary Nu.Q® Cancer... Read More

Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready HENDERSON, Nev. , March 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to... Read More

Volition will showcase presentations from Dr. Sue Ettinger , aka Dr. Sue Cancer Vet, Dr. Brett Cordes , DVM, and Dr. Tom Butera , DVM Representatives will also be available at exhibition booth #2943 HENDERSON, Nev. , Feb. 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is pleased to announce our participation in the 97th Annual Western Veterinary... Read More

Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" activation and inhibition in... Read More

HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET , featuring Volition company management Dr. Andrew Retter , Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q® NETs... Read More

HENDERSON, Nev. , Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients. Findings published in the paper currently undergoing peer... Read More

HENDERSON, Nev. , Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide. Sold over 110,000 Nu.Q® Vet Cancer... Read More

Volition to participate in the upcoming 14 th Annual LifeSci Partners Corporate Access Event on January 15 th , 2025 at the Beacon Grand Hotel in San Francisco . HENDERSON, Nev. , Dec. 12, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained LifeSci Advisors, LLC ("LSA") a premiere life sciences corporate and... Read More

HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX ) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q ® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT ( LDCT ) scan, in patients suspected of lung cancer. The 800-patient prospective study was led by Professor... Read More

Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648... Read More

Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at... Read More

Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this... Read More

HENDERSON, Nev. , Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024 . Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner... Read More

HENDERSON, Nev. , Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report , from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q ® NETs could be used to predict patients at greater risk of deteriorating from sepsis. The symposium explored research findings from three large, independent... Read More

HENDERSON, Nev. , Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024 , the annual congress of the European Society of Intensive Care Medicine, earlier this week. Given the extensive size and scope of the three independent studies on the potential use of... Read More

HENDERSON, Nev. , Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024 , during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The... Read More

HENDERSON, Nev. , Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024 . Dr. Rubin has also been appointed as a member of the Audit Committee... Read More

HENDERSON, Nev. , Sept. 11, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q®... Read More

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of 2024. Volition management will host a conference call tomorrow, August 15 at... Read More

$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev. , Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its... Read More

Conference call to take place on Thursday August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , Aug. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2024, in addition to providing a business update. Details of this event... Read More

HENDERSON, Nev. , July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio. PharmaVentures has been engaged to act as an advisor to Volition to help secure... Read More

HENDERSON, Nev. , June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024. Volition's mid-year review encompasses key highlights including: Expanding access to the Nu.Q® Vet Cancer Test – now available for purchase in 15 countries worldwide.... Read More

HENDERSON, Nevada , May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds , President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City . Presentation Details: Date: Wednesday, June 5, 2024 Time: 3.30 pm ET (Track 3)... Read More

Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024. Volition management will host a conference call tomorrow, May 14 at 8:30 a.m.... Read More

Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , May 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, May 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024, in addition to providing a business update. Details of this event can also be... Read More

HENDERSON, Nev. , April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech , a leading veterinary diagnostics company. Antech's... Read More

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023 . Volition management will host a conference call... Read More

Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , March 21, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023, in addition to providing a business update. Details of... Read More

HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan . Volition's supply agreement enables Fujifilm Vet Systems to sell and perform... Read More

HENDERSON, Nev. , March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024 . Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs. Andrew is an Intensive Care Consultant at Guy's and St.... Read More

HENDERSON, Nev. , Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test. The webinar takes place on Tuesday, February 13 th at 10:30 AM U.S. Eastern Time and will include updates from Volition's Mr. Gael Forterre... Read More

HENDERSON, Nev. , Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year. Volition's major achievements in 2023 include: Launching the Nu.Q® Vet Cancer Test in some significant markets through several licensing, supply and/or distribution agreements. Establishing several... Read More

HENDERSON, Nev. , Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million ) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium . Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its clinical... Read More

Conference call to discuss financial and operational results scheduled for Wednesday, November 15 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2023 . Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S.... Read More

Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev. , Nov. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2023, in addition to providing a business update. Details of this... Read More

HENDERSON, Nev. , Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland . VPG is the first-to-market diagnostic laboratory in the UK and Ireland to offer the Nu.Q® Vet Cancer... Read More

HENDERSON, Nev. , Oct. 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology. In early-stage cancer, it is difficult to detect cancer-derived circulating tumor DNA (ctDNA) in the blood because it may comprise... Read More

HENDERSON, Nev. , Oct. 19, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper 1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis. The 150-patient study published in Annals of... Read More

HENDERSON, Nev. , Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler , U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes,... Read More

HENDERSON, Nev. , Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology. Dr. Jake Micallef , Chief Scientific Officer at Volition, said: "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in... Read More

HENDERSON, Nev. , Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader ("KOL") roundtable on sepsis management. Remi Rabeuf , Lifecycle Leader at Volition, said: "We were delighted to bring together some of the world's leading experts in sepsis to explore the potential of... Read More

HENDERSON, Nev. , Oct. 2, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 st at ESMO 2023, the annual congress of the European Society for Medical Oncology. The webinar takes place on Thursday, October 26 th at 10:30 AM U.S. Eastern Time and will... Read More

HENDERSON, Nev. , Sept. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis. Chaired by Professor Djillali Annane , Professor of Medicine at University Paris Saclay-UVSQ , and one of the world's leading specialists in sepsis,... Read More

Conference call to discuss financial and operational results scheduled for Tuesday, August 15 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Aug. 14, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2023 . Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time... Read More

Conference call to take place on Tuesday, August 15 at 8:30 a.m. Eastern Time HENDERSON, Nev , Aug. 9, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, August 15 at 8.30 a.m. Eastern Time to discuss its financial and operating results for the second quarter 2023, in addition to providing a business update. Details of this event can also be... Read More

HENDERSON, Nev. , June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to... Read More

HENDERSON, Nev. , June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million , before deducting underwriting commissions and other offering expenses payable by Volition. All... Read More

HENDERSON, Nev. , June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering... Read More

HENDERSON, Nev. , May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the... Read More

HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers. The study was led by Dr. Heather Wilson-Robles , a leading veterinary oncologist... Read More

Conference call to discuss financial and operational results scheduled for Thursday, May 11 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2023 . Volition management will host a conference call tomorrow, May 11 at 8:30 a.m. U.S. Eastern Time to... Read More

Conference call to take place on Thursday May 11 at 08:30 a.m. Eastern Time Capital Markets Day - Thursday May 11 at 2:00 p.m. Eastern Time HENDERSON, Nev. , May 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday May 11 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2023, in addition to... Read More

HENDERSON, Nev. , April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023 , at 2 p.m. U.S. Eastern Time. Volition's executive team will be joined by Key Opinion Leaders: Dr. Andy Retter (Intensive Care Consultant) and Veterinary Oncologists, Professor... Read More

Conference call to discuss financial and operational results scheduled for Thursday, March 16 , at 8:30 a.m. U.S. Eastern Time Executed global licensing and supply agreement with Heska Corporation ("Heska") to distribute Nu.Q® Vet Cancer Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones. Volition will also receive ongoing additional... Read More

Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev. , March 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 16 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the full fiscal year 2022, in addition to providing a business update. Event: VolitionRx Limited Full... Read More

HENDERSON, Nevada , Feb. 22, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 4,945,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $1.75 per share. The gross proceeds to Volition from... Read More

HENDERSON, Nev. , Feb. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering... Read More

HENDERSON, Nev. , Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the... Read More

HENDERSON, Nev. , Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (NASDAQ: HSKA) ("Heska"). The Nu.Q® test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest... Read More

HENDERSON, Nev. , Jan. 20, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition's Nu.Q® Vet commercial strategy. The webinar takes place on Thursday, January 26 th at 12 noon U.S. Eastern Time and will include updates from Dr. Tom Butera (Chief Executive Officer) and Dr. Heather Wilson... Read More

HENDERSON, Nev. , Jan. 12, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S. Dr. Tom Butera , Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "IDEXX is a global leader in pet healthcare... Read More

HENDERSON, Nev , Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations. Volition's major achievements in 2022 include: Expanding access to the Nu.Q® Vet Cancer Test on a... Read More